依达拉奉联合奥扎格雷治疗急性缺血性脑卒中的疗效观察

目的:探讨依达拉奉联合奥扎格雷治疗缺血性脑卒中(IS)的临床疗效及安全性.方法:选取80例急性IS病人,根据随机数字法分为对照组和观察组,对照组采用奥扎格雷治疗,观察组采用依达拉奉联合奥扎格雷治疗,于治疗后7 d、14 d、30 d比较2组在日常生活活动能力量表(ADL)指数评分和改良爱丁堡-斯堪的那维亚量表(SSS)评分、临床疗效及不良反应等方面的差异.结果:观察组病人治疗后7 d、14 d和30 d的SSS评分均较对照组明显降低(P<0.01);观察组病人治疗后14 d和30 d的ADL指数评分均较对照组显著提高(P<0.01);观察组病人临床疗效优于对照组(P<0.05);治疗期间2组均未出现明显的不良反应.结论:依达拉奉联合奥扎格雷治疗能明显改善IS病人的神经功能缺损及日常生活能力,疗效显著、不良反应少,值得临床推广.

Effect of edaravone combined with ozagrel in the treatment of acute ischemic stroke

Objective:To investigate the clinical efficacy and safety of edaravone combined with ozagrel in the treatment of ischemic stroke(IS).Methods:Eighty patients with acute ischemic stroke were randomly devided into the control group and observation group according to the random number methods.The control group and observation group were treated with ozagrel and edaravone combined with ozagrel,respectively.The score of modified Edinburgh Scandinavia Scandinavian scale(MESSS),index score of activity of daily living scale(ADL),clinical efficacy and adverse reaction between two groups were compared 7 d,14 d and 30 d after treatment.Results:Compared with the control group,the MESSS score and ADL index score in observation group significantly decreased and increased 7 d,14 d and 30 d after treatment,respectively(P<0.01).The clinical efficacy in observation group was better than that in control group(P<0.05).No obvious adverse reaction in the two groups was found during the treatment.Conclusions:The treatment of edaravone combined with ozagrel can significantly improve the neural function and daily living ability,which is good clinical efficacy,less adverse reaction,and worthy of clinical promotion.